Imeglimin预防肠易激综合征大鼠模型的内脏超敏反应和结肠高渗透性。

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY Journal of pharmacological sciences Pub Date : 2023-09-01 DOI:10.1016/j.jphs.2023.07.002

Tsukasa Nozu , Saori Miyagishi , Masatomo Ishioh , Kaoru Takakusaki , Toshikatsu Okumura

{"title":"Imeglimin预防肠易激综合征大鼠模型的内脏超敏反应和结肠高渗透性。","authors":"Tsukasa Nozu , Saori Miyagishi , Masatomo Ishioh , Kaoru Takakusaki , Toshikatsu Okumura","doi":"10.1016/j.jphs.2023.07.002","DOIUrl":null,"url":null,"abstract":"<div><p>Visceral hypersensitivity and leaky gut, which are mediated <em>via</em> corticotropin-releasing factor (CRF) and Toll-like receptor 4 are key pathophysiology of irritable bowel syndrome (IBS). Metformin was reported to improve these gastrointestinal (GI) changes. In this study, we attempted to determine the effects of imeglimin, which was synthesized from metformin on GI function in IBS rat models. Imeglimin blocked lipopolysaccharide- or CRF-induced visceral hypersensitivity and colonic hyperpermeability. These effects were prevented by compound C or naloxone. These results suggest that imeglimin may be effective for the treatment of IBS by improved visceral sensation and colonic barrier <em>via</em> AMPK and opioid receptor.</p></div>","PeriodicalId":16786,"journal":{"name":"Journal of pharmacological sciences","volume":"153 1","pages":"Pages 26-30"},"PeriodicalIF":3.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model\",\"authors\":\"Tsukasa Nozu , Saori Miyagishi , Masatomo Ishioh , Kaoru Takakusaki , Toshikatsu Okumura\",\"doi\":\"10.1016/j.jphs.2023.07.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Visceral hypersensitivity and leaky gut, which are mediated <em>via</em> corticotropin-releasing factor (CRF) and Toll-like receptor 4 are key pathophysiology of irritable bowel syndrome (IBS). Metformin was reported to improve these gastrointestinal (GI) changes. In this study, we attempted to determine the effects of imeglimin, which was synthesized from metformin on GI function in IBS rat models. Imeglimin blocked lipopolysaccharide- or CRF-induced visceral hypersensitivity and colonic hyperpermeability. These effects were prevented by compound C or naloxone. These results suggest that imeglimin may be effective for the treatment of IBS by improved visceral sensation and colonic barrier <em>via</em> AMPK and opioid receptor.</p></div>\",\"PeriodicalId\":16786,\"journal\":{\"name\":\"Journal of pharmacological sciences\",\"volume\":\"153 1\",\"pages\":\"Pages 26-30\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmacological sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1347861323000403\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1347861323000403","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

通过促肾上腺皮质激素释放因子（CRF）和Toll样受体4介导的内脏超敏反应和肠漏是肠易激综合征（IBS）的关键病理生理学。据报道，二甲双胍可改善这些胃肠道（GI）变化。在这项研究中，我们试图确定由二甲双胍合成的依格列明对IBS大鼠模型胃肠道功能的影响。Imeglimin阻断脂多糖或CRF诱导的内脏超敏反应和结肠高渗透性。这些作用通过化合物C或纳洛酮来预防。这些结果表明，格列美脲可能通过AMPK和阿片受体改善内脏感觉和结肠屏障，从而有效治疗IBS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model

Visceral hypersensitivity and leaky gut, which are mediated via corticotropin-releasing factor (CRF) and Toll-like receptor 4 are key pathophysiology of irritable bowel syndrome (IBS). Metformin was reported to improve these gastrointestinal (GI) changes. In this study, we attempted to determine the effects of imeglimin, which was synthesized from metformin on GI function in IBS rat models. Imeglimin blocked lipopolysaccharide- or CRF-induced visceral hypersensitivity and colonic hyperpermeability. These effects were prevented by compound C or naloxone. These results suggest that imeglimin may be effective for the treatment of IBS by improved visceral sensation and colonic barrier via AMPK and opioid receptor.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of pharmacological sciences 医学-药学

CiteScore

6.20

自引率

2.90%

发文量

104

审稿时长

31 days

期刊介绍： Journal of Pharmacological Sciences (JPS) is an international open access journal intended for the advancement of pharmacological sciences in the world. The Journal welcomes submissions in all fields of experimental and clinical pharmacology, including neuroscience, and biochemical, cellular, and molecular pharmacology for publication as Reviews, Full Papers or Short Communications. Short Communications are short research article intended to provide novel and exciting pharmacological findings. Manuscripts concerning descriptive case reports, pharmacokinetic and pharmacodynamic studies without pharmacological mechanism and dose-response determinations are not acceptable and will be rejected without peer review. The ethnopharmacological studies are also out of the scope of this journal. Furthermore, JPS does not publish work on the actions of biological extracts unknown chemical composition.